The physician orders an injection of dexamethasone (Decadron) 6mg IM for a patient.

The available stock is dexamethasone 4mg/1ml in a 5ml multidose vial.

How many mLs of this medication will the nurse prepare?

Choice A rationale:

Constipation is not typically associated with hyperthyroidism. In fact, one of the symptoms of hyperthyroidism is increased bowel movement. This is due to the increased metabolic rate caused by the overproduction of hormones from the thyroid gland.

Choice B rationale:

Weight gain is not a common symptom of hyperthyroidism. On the contrary, weight loss is one of the symptoms of this condition. This is because hyperthyroidism speeds up the body’s metabolism, causing increased calorie burning and significant weight loss. Choice C rationale:

Sensitivity to cold is not a symptom of hyperthyroidism. Instead, individuals with hyperthyroidism often have an increased sensitivity to heat. This is due to the increased metabolic rate which can cause excessive sweating and hot flashes.

Choice D rationale:

Frequent mood changes are a common symptom of hyperthyroidism. The overproduction of hormones by the thyroid gland can lead to symptoms such as irritability and restlessness. Additionally, other symptoms such as difficulty sleeping can also contribute to mood changes.

Choice A rationale:

Zidovudine, also known as AZT, is a medication used for the treatment of human immunodeficiency virus (HIV) infection. One of the major dose-limiting toxic effects of Zidovudine is hematologic toxicity, which manifests clinically as anemia, neutropenia, and sometimes as platelet deficits with onset after several weeks of treatment. This hematologic toxicity is essentially a form of bone marrow suppression. Therefore, bone marrow suppression is the dose-limiting adverse effect of zidovudine therapy.

Choice B rationale:

Retinitis is not a known dose-limiting adverse effect of zidovudine. While zidovudine has a range of side effects, retinitis is not commonly associated with its use.

Choice C rationale:

Renal toxicity is not a known dose-limiting adverse effect of zidovudine. While zidovudine can have various side effects, renal toxicity is not typically one of them.

Choice D rationale:

Hepatotoxicity is not the dose-limiting adverse effect of zidovudine. While severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of zidovudine, it is not considered the dose-limiting adverse effect. The dose-limiting adverse effect is more specifically related to hematologic toxicity, which includes bone marrow suppression.